Technical Analysis for GNHAY - Vifor Pharma Ag ADR

Grade Last Price % Change Price Change
F 28.7 -5.75% -1.7500
GNHAY closed down 5.75 percent on Friday, January 22, 2021, on 71 percent of normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical GNHAY trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Gapped Down Weakness 0.00%
Hot IPO Pullback Bullish Swing Setup -5.75%
Narrow Range Bar Range Contraction -5.75%
Hot IPO Pullback Bullish Swing Setup -5.75%
Narrow Range Bar Range Contraction -5.75%
Gapped Down Weakness -5.75%
Older End-of-Day Signals for GNHAY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vifor Pharma Ag ADR Description

Vifor Pharma AG researches, develops, produces, and markets pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used in the intravenous treatment of iron deficiency; Mircera, a long-acting erythropoiesis-stimulating agent to treat symptomatic anaemia associated with the chronic kidney disease (CKD); Venofer, a solution for iron sucrose used in the intravenous treatment of iron deficiency; and Invokana to treat diabetic kidney disease. It provides Retacrit to treat anaemia due to CKD; Velphoro, a non-calcium, iron-based, and chewable phosphate binder to control the phosphate levels in the blood of adults with CKD; and Veltassa, a sodium-free potassium binder to treat hyperkalaemia in adult patients. The company offers Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman; Broncho-Vaxom, to treat recurrent respiratory infections; Uro-Vaxom to treat recurrent urinary tract infections; Doxium, an oral treatment for diabetic retinopathy and haemorrhoidal syndrome; and Uro-Vaxom to treat recurrent urinary tract infections. It provides Rayaldee, which is in pre commercial stage to treat secondary hyperparathyroidism in patients with CKD; Avacopan, which is in pre commercial stage to treat orphan and rare renal diseases; Vadadustat, which is Phase III clinical trials to treat anaemia due to CKD; CR845, which is in Phase III clinical trials to treat CKD disease-associated pruritus; CCX140, which is in Phase II clinical trials to treat patients with focal segmental glomerulosclerosis; and VIT-2763, which is in Phase II clinical trial to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Zurich, Switzerland.


Classification

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Keywords: Medical Specialties E Commercial Pharmaceutical Diabetes Organ Systems Pharmaceutical Products Potassium Infant Calcium Kidney Sclerosis Cx Deficiency Malt Anatomy Chronic Kidney Kidney Disease Chronic Kidney Disease Gale Thyroid Idis Kidney Diseases Urinary Tract Infection Renal Disease Diabetic Retinopathy Fresenius Urinary Tract Infections A Solution Iron Deficiency Pruritus Retinopathy Hyperparathyroidism Renal Diseases Secondary Hyperparathyroidism Vifor Pharma Ccx140 Ckd Disease Associated Pruritus Cr845 Diabetic Kidney Disease Ferinject/Injectafer Focal Segmental Glomerulosclerosis Galenica Haemorrhoidal Syndrome Maltofer Markets Pharmaceutical Products Rare Renal Diseases Recurrent Respiratory Infections Recurrent Urinary Tract Infections Retacrit Thalassemia Treatment For Diabetic Retinopathy And Haemorrhoidal Syndrome Vadadustat Velphoro Venofer Vit 2763

Is GNHAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 37.709
52 Week Low 28.7
Average Volume 792
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 30.7785
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line -0.2773
MACD Signal Line -0.0679
MACD Histogram -0.2094
Fundamentals Value
Market Cap 9.31 Billion
Num Shares 324 Million
EPS
Price-to-Sales 4.69
Price-to-Book 2.68
Dividend 0.41
Dividend Yield 1.43%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.7000
Resistance 3 (R3) 28.7000 28.7000 28.7000
Resistance 2 (R2) 28.7000 28.7000 28.7000 28.7000
Resistance 1 (R1) 28.7000 28.7000 28.7000 28.7000 28.7000
Pivot Point 28.7000 28.7000 28.7000 28.7000 28.7000
Support 1 (S1) 28.7000 28.7000 28.7000 28.7000 28.7000
Support 2 (S2) 28.7000 28.7000 28.7000 28.7000
Support 3 (S3) 28.7000 28.7000 28.7000
Support 4 (S4) 28.7000